PTC Therapeutics Inc (PTCT)

12.09
1.01 9.12
NASDAQ : Health Care
Prev Close 11.08
Open 11.28
Day Low/High 11.20 / 12.20
52 Wk Low/High 5.27 / 60.93
Volume 906.84K
Avg Volume 2.26M
Exchange NASDAQ
Shares Outstanding 34.32M
Market Cap 376.81M
EPS -5.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

Materials, financials, cyclicals and health care names tilt the scale to the bullish side.

Spinal Muscular Atrophy Program Advances Into Phase 2 Clinical Studies In SMA Patients With RG7916

Spinal Muscular Atrophy Program Advances Into Phase 2 Clinical Studies In SMA Patients With RG7916

- Initiated SUNFISH study to evaluate RG7916 in Type 2/3 SMA patients -

RSI Alert: PTC Therapeutics (PTCT) Now Oversold

RSI Alert: PTC Therapeutics (PTCT) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

PTC Therapeutics Getting Cold Shoulder From Regulators on Duchenne Drug Appeal

PTC Therapeutics Getting Cold Shoulder From Regulators on Duchenne Drug Appeal

On Monday, PTC said the U.S. Food and Drug Administration denied an appeal of the Translarna refuse-to-file letter issued last February.

Commit To Purchase PTC Therapeutics At $5, Earn 22% Using Options

Commit To Purchase PTC Therapeutics At $5, Earn 22% Using Options

Investors considering a purchase of PTC Therapeutics Inc stock, but tentative about paying the going market price of $10.24/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $5 strike, which has a bid at the time of this writing of $1.10.

PTC Therapeutics Recognizes World Duchenne Awareness Day by Announcing Winners of Global Duchenne Muscular Dystrophy Patient Group Awards and Expanding Disease State Awareness Website

PTC Therapeutics Recognizes World Duchenne Awareness Day by Announcing Winners of Global Duchenne Muscular Dystrophy Patient Group Awards and Expanding Disease State Awareness Website

- STRIVE Awards Program Recognizes Excellence and Innovation in the Duchenne Muscular Dystrophy Community -

10 Best-Performing Stocks This Earnings Season

10 Best-Performing Stocks This Earnings Season

Which stocks have had the highest gains following earnings? Bespoke Investment came up with a list of the 40 stocks that had the best performance on their earnings reaction days.

Today's Perilous Reversal Stock: PTC Therapeutics (PTCT)

Today's Perilous Reversal Stock: PTC Therapeutics (PTCT)

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a "perilous reversal" (up big yesterday but down big today) candidate

Strong On High Volume: PTC Therapeutics (PTCT)

Strong On High Volume: PTC Therapeutics (PTCT)

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a strong on high relative volume candidate

PTC Therapeutics Duchenne Drug Stuck on Conditional Approval Status in Europe

PTC Therapeutics Duchenne Drug Stuck on Conditional Approval Status in Europe

European regulators have delayed PTC Therapeutics' request for permanent approval of its Duchenne muscular dystrophy drug Translarna.

Strong On High Relative Volume: PTC Therapeutics (PTCT)

Strong On High Relative Volume: PTC Therapeutics (PTCT)

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a strong on high relative volume candidate

NHS England Enables Access To Translarna™ ¿ (ataluren) For Patients With Nonsense Mutation Duchenne Muscular Dystrophy

NHS England Enables Access To Translarna™ ¿ (ataluren) For Patients With Nonsense Mutation Duchenne Muscular Dystrophy

--Important decision allows reimbursed access to Translarna, the first approved therapy to treat the underlying cause of Duchenne muscular dystrophy--

Commit To Purchase PTC Therapeutics At $5, Earn 30% Using Options

Commit To Purchase PTC Therapeutics At $5, Earn 30% Using Options

Investors considering a purchase of PTC Therapeutics Inc shares, but tentative about paying the going market price of $6.65/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $5 strike, which has a bid at the time of this writing of $1.50.

Biotech Stock Mailbag: Sarepta! Always More Sarepta. And Gilead, Too

Biotech Stock Mailbag: Sarepta! Always More Sarepta. And Gilead, Too

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

PTC Therapeutics (PTCT) Marked As A Dead Cat Bounce Stock

PTC Therapeutics (PTCT) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a "dead cat bounce" (down big yesterday but up big today) candidate

PTC Therapeutics (PTCT) Weak On High Volume

PTC Therapeutics (PTCT) Weak On High Volume

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a weak on high relative volume candidate

PTC Therapeutics (PTCT) Marked As A Dead Cat Bounce Stock

PTC Therapeutics (PTCT) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a "dead cat bounce" (down big yesterday but up big today) candidate

GPM Reminds Investors Of The May 2 Deadline In The Class Action Lawsuit Against PTC Therapeutics, Inc. And Encourages Investors To Contact The Firm

GPM Reminds Investors Of The May 2 Deadline In The Class Action Lawsuit Against PTC Therapeutics, Inc. And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming May 2, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased PTC Therapeutics, Inc.